Several studies, including ours, reported that weight loss through calorie restriction or the SGLT2 inhibitor dapagliflozin can induce a significant reduction in serum sDPP-4/CD26 in people with type 2 diabetes.21 This evidence concerns the gene DPP4 and type 2 diabetes mellitus.